Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free AYTU Stock Alerts

Aytu BioPharma (AYTU) Financials

Aytu BioPharma logo
$2.08 -0.05 (-2.35%)
Closing price 07/29/2026 04:00 PM Eastern
Extended Trading
$2.07 -0.01 (-0.48%)
As of 07/29/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Aytu BioPharma

Annual Income Statements for Aytu BioPharma

This table shows Aytu BioPharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 -7.72 -28 -23 -10 -27 -14 -58 -109 -17 -16 -14
Consolidated Net Income / (Loss)		 -7.72 -28 -23 -10 -27 -14 -58 -109 -17 -16 -14
Net Income / (Loss) Continuing Operations		 -7.72 -28 -23 -10 -27 -14 -58 -109 -17 -13 -14
Total Pre-Tax Income 		-7.75 -28 -23 -10 -27 -14 -58 -109 -17 -10 -14
Total Operating Income		 -7.63 -22 -20 -20 -17 -21 -59 -110 -17 -1.59 -7.83
Total Gross Profit		 0.17 1.61 1.80 1.61 5.12 19 29 52 67 49 46
Total Revenue		 0.26 2.56 3.22 3.66 7.32 28 66 97 107 65 66
Operating Revenue		 0.26 2.56 3.22 3.66 7.32 28 66 97 107 65 66
Total Cost of Revenue		 0.09 0.96 1.42 2.05 2.20 8.28 36 44 41 16 21
Operating Cost of Revenue		 0.09 0.96 1.42 2.05 2.20 8.28 36 44 41 16 21
Total Operating Expenses		 7.81 23 22 21 22 40 88 162 84 51 54
Selling, General & Admin Expense		 3.98 8.52 17 18 19 20 26 31 29 20 17
Marketing Expense		 - - - - - 11 30 39 41 22 21
Research & Development Expense		 3.42 6.32 1.35 0.17 0.59 1.72 5.62 13 4.10 2.77 1.33
Amortization Expense		 0.09 0.66 1.71 1.55 2.14 4.49 6.01 5.84 4.79 3.68 3.68
Impairment Charge		 0.00 7.50 1.27 1.86 0.00 0.20 13 75 5.71 0.00 8.26
Restructuring Charge		 - - - - - 3.02 7.81 - 0.00 2.16 2.10
Total Other Income / (Expense), net		 -0.11 -6.48 -2.38 9.51 -10 7.51 0.84 1.02 0.01 -8.79 -5.92
Interest Expense		 0.11 5.49 2.53 0.75 0.54 0.32 1.57 -0.17 4.96 5.65 3.70
Other Income / (Expense), net		 0.00 -0.01 0.21 10 -9.75 7.83 2.41 0.85 4.98 -3.13 -2.22
Income Tax Expense		 -0.02 - - - - 0.00 0.26 -0.11 0.00 2.14 0.44
Net Income / (Loss) Discontinued Operations		 - - - - - - - - - -3.32 0.62
Basic Earnings per Share		 ($10.07) ($323.70) ($48.30) ($15.31) ($3.48) ($3.01) ($3.48) ($74.01) ($5.11) ($2.86) ($2.16)
Weighted Average Basic Shares Outstanding		 767.33K 87.06K 466.02K 665.61K 7.79M 4.52M 16.75M 1.47M 3.34M 5.54M 6.28M
Weighted Average Diluted Shares Outstanding		 767.33K 87.06K 466.02K 665.61K 7.79M 4.52M 16.75M 1.47M 5.53M 6.15M 9.91M
Weighted Average Basic & Diluted Shares Outstanding		 767.33K 87.06K 466.02K 665.61K 7.79M 4.52M 16.75M 62.43M 5.53M 6.15M 9.91M

Quarterly Income Statements for Aytu BioPharma

This table shows Aytu BioPharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -8.12 -0.22 -2.89 -4.62 1.47 0.79 3.99 -20 1.97 -11 -5.62
Consolidated Net Income / (Loss)		 -8.12 -0.22 -2.89 -4.62 1.47 0.79 3.99 -20 1.97 -11 -5.62
Net Income / (Loss) Continuing Operations		 -7.47 0.62 -2.29 -3.38 1.09 0.67 3.94 -20 1.97 -11 -5.62
Total Pre-Tax Income 		-7.47 1.40 -1.77 -2.54 1.50 0.38 3.82 -19 1.97 -11 -5.61
Total Operating Income		 -0.87 3.15 -1.60 -2.27 -0.93 -1.70 2.42 -7.62 -1.50 -1.97 -4.06
Total Gross Profit		 13 15 10 11 12 11 13 10 9.19 9.62 7.60
Total Revenue		 18 19 14 15 17 16 18 15 14 15 12
Operating Revenue		 18 19 14 15 17 16 18 15 14 15 12
Total Cost of Revenue		 4.78 4.15 3.66 3.54 4.59 5.44 5.65 4.88 4.70 5.54 4.81
Operating Cost of Revenue		 4.78 4.15 3.66 3.54 4.59 5.44 5.65 4.88 4.70 5.54 4.81
Total Operating Expenses		 14 11 12 13 13 12 10 18 11 12 12
Selling, General & Admin Expense		 6.30 4.80 4.83 4.03 5.13 4.45 4.11 3.70 4.92 5.07 4.97
Marketing Expense		 6.09 5.22 5.35 5.42 5.66 5.27 5.19 4.78 5.32 6.00 5.93
Research & Development Expense		 0.60 0.52 0.61 1.04 0.43 0.52 0.16 0.22 0.00 0.00 0.00
Amortization Expense		 0.92 0.92 0.92 0.92 0.92 0.92 0.92 0.92 0.44 0.53 0.76
Restructuring Charge		 0.00 0.00 0.24 1.91 0.78 1.32 0.00 - 0.00 0.00 0.00
Total Other Income / (Expense), net		 -6.61 -1.75 -0.17 -0.26 2.43 2.08 1.40 -12 3.47 -8.61 -1.54
Interest Expense		 1.28 1.27 1.26 1.85 0.99 1.08 0.90 0.73 0.52 0.56 0.44
Other Income / (Expense), net		 -5.32 -0.48 1.09 1.58 3.42 3.16 2.30 -11 3.99 -8.05 -1.11
Income Tax Expense		 0.00 0.78 0.52 0.84 0.41 -0.28 -0.12 0.44 0.00 0.00 0.01
Net Income / (Loss) Discontinued Operations		 -0.65 -0.84 -0.60 -1.24 0.38 0.12 0.05 0.06 0.00 0.00 0.00
Basic Earnings per Share		 ($1.48) ($0.04) ($0.52) ($0.83) $0.24 $0.13 $0.65 ($3.18) $0.21 ($1.05) ($0.53)
Weighted Average Basic Shares Outstanding		 5.48M 5.52M 5.53M 5.54M 6.07M 6.13M 6.13M 6.28M 9.44M 10.04M 10.51M
Diluted Earnings per Share		 ($1.48) ($0.04) ($0.52) ($0.83) ($0.15) ($0.26) $0.21 - ($0.08) ($1.05) ($0.53)
Weighted Average Diluted Shares Outstanding		 5.48M 5.52M 5.53M 6.15M 9.10M 8.49M 8.20M 9.91M 19.48M 10.04M 10.51M
Weighted Average Basic & Diluted Shares Outstanding		 5.57M 5.57M 5.57M 6.15M 6.15M 6.17M 6.17M 9.91M 10.19M 10.73M 10.73M

Annual Cash Flow Statements for Aytu BioPharma

This table details how cash moves in and out of Aytu BioPharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Net Change in Cash & Equivalents		 4.71 0.70 -7.18 6.23 4.18 37 1.57 -31 3.63 -2.98 11
Net Cash From Operating Activities		 -6.63 -11 -14 -16 -14 -28 -26 -29 -5.13 -1.39 -1.94
Net Cash From Continuing Operating Activities		 -6.63 -11 -14 -16 -14 -28 -26 -29 -5.13 -1.39 -1.94
Net Income / (Loss) Continuing Operations		 -7.72 -28 -23 -10 -27 -14 -58 -109 -17 -16 -14
Consolidated Net Income / (Loss)		 -7.72 -28 -23 -10 -27 -14 -58 -109 -17 -16 -14
Depreciation Expense		 0.12 0.87 4.36 2.59 2.73 5.71 9.20 10 8.82 6.73 5.38
Amortization Expense		 0.12 5.25 0.34 - - 0.53 -0.04 -0.13 0.56 0.60 0.11
Non-Cash Adjustments To Reconcile Net Income		 0.26 9.61 5.25 -7.62 11 3.26 21 81 9.32 12 12
Changes in Operating Assets and Liabilities, net		 0.59 1.79 -1.04 -0.72 -0.21 -24 1.72 -11 -6.77 -4.66 -5.73
Net Cash From Investing Activities		 -1.00 -5.30 -3.53 -0.48 -1.06 -5.66 -2.78 -3.25 -0.12 -0.33 -2.56
Net Cash From Continuing Investing Activities		 -1.00 -5.30 -3.53 -0.48 -1.06 -5.66 -2.78 -3.25 -0.12 -0.33 -2.56
Purchase of Property, Plant & Equipment		 0.00 -1.29 -0.86 -0.47 -0.56 0.00 -2.34 - - -0.33 -0.23
Acquisitions		 -1.00 -2.00 -0.02 - - -5.85 -16 - - 0.00 -3.00
Sale of Property, Plant & Equipment		 - 0.00 - - - - - - - 0.00 0.67
Net Cash From Financing Activities		 12 17 10 23 19 71 30 1.53 8.87 -1.26 15
Net Cash From Continuing Financing Activities		 12 17 10 20 19 71 30 1.53 8.87 -1.26 15
Repayment of Debt		 0.00 -0.33 - - 0.00 -19 -55 -21 -2.44 -15 4.76
Issuance of Debt		 7.40 5.18 - 0.00 5.00 3.19 51 15 0.00 13 1.86
Issuance of Common Equity		 0.00 0.20 0.74 12 - 66 40 12 16 3.47 15
Other Financing Activities, net		 5.00 12 9.54 9.74 0.38 27 -6.09 -4.41 -4.27 -2.57 -6.02
Cash Interest Paid		 - - - - 0.00 1.04 1.25 3.15 3.81 4.04 2.82
Cash Income Taxes Paid		 - - - - - - - - 0.00 1.61 1.42

Quarterly Cash Flow Statements for Aytu BioPharma

This table details how cash moves in and out of Aytu BioPharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -3.02 -0.44 0.23 0.25 0.10 0.29 -2.23 13 1.68 -2.61 -3.31
Net Cash From Operating Activities		 -0.21 -0.14 -0.25 -0.79 -1.19 2.91 -6.46 2.80 -0.62 3.68 -4.18
Net Cash From Continuing Operating Activities		 -0.21 -0.14 -0.25 -0.79 -1.19 2.91 -6.46 2.80 -0.62 3.68 -4.18
Net Income / (Loss) Continuing Operations		 -8.12 -0.22 -2.89 -4.62 1.47 0.79 3.99 -20 1.97 -11 -5.62
Consolidated Net Income / (Loss)		 -8.12 -0.22 -2.89 -4.62 1.47 0.79 3.99 -20 1.97 -11 -5.62
Depreciation Expense		 2.23 1.40 1.53 1.56 1.33 1.29 1.29 1.29 0.80 0.89 1.12
Amortization Expense		 0.15 0.15 0.16 0.13 0.03 0.03 0.03 0.03 0.03 0.03 0.03
Non-Cash Adjustments To Reconcile Net Income		 6.89 2.21 0.52 2.18 -3.17 -2.44 -2.01 20 -3.39 9.36 2.10
Changes in Operating Assets and Liabilities, net		 -1.36 -3.68 0.42 -0.04 -0.85 3.24 -9.76 1.64 -0.02 3.98 -1.81
Net Cash From Financing Activities		 -2.73 -0.13 0.53 1.07 0.91 -2.76 4.30 13 2.30 -6.26 0.87
Net Cash From Continuing Financing Activities		 -2.73 -0.13 0.53 1.07 0.91 -2.76 4.30 13 2.30 -6.26 0.87
Repayment of Debt		 -0.02 -0.56 0.51 -15 -0.46 -0.47 -0.46 6.16 -0.46 -0.47 -0.46
Issuance of Debt		 -0.35 - - 13 1.88 -0.26 6.02 -5.78 5.81 -5.80 1.34

Annual Balance Sheets for Aytu BioPharma

This table presents Aytu BioPharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Total Assets		 18 24 15 21 35 153 266 138 136 118 124
Total Current Assets		 8.04 10 3.03 9.47 15 75 105 60 71 62 79
Cash & Equivalents		 7.35 8.05 0.80 7.01 11 48 50 19 23 20 31
Accounts Receivable		 0.16 0.16 0.53 0.58 1.74 5.63 28 22 29 24 31
Inventories, net		 0.04 0.52 1.31 1.34 1.44 10.00 16 11 12 12 11
Prepaid Expenses		 0.49 0.34 0.31 0.44 0.96 5.72 9.78 7.38 7.16 5.10 5.64
Plant, Property, & Equipment, net		 0.03 0.23 0.65 0.22 0.20 0.00 0.00 3.03 1.82 0.69 0.53
Total Noncurrent Assets		 10 14 11 11 19 78 160 75 64 56 44
Intangible Assets		 0.71 0.49 0.44 0.25 0.00 49 85 71 59 52 42
Other Noncurrent Operating Assets		 9.33 13 11 11 19 0.67 9.17 4.04 4.60 3.01 2.27
Total Liabilities & Shareholders' Equity		 18 24 15 21 35 153 266 138 136 118 124
Total Liabilities		 2.57 14 11 7.64 28 58 128 93 97 90 105
Total Current Liabilities		 1.48 10 3.61 3.39 5.37 29 109 64 69 62 63
Short-Term Debt		 - 0.00 0.26 0.55 1.08 1.70 25 3.81 1.65 4.25 11
Accounts Payable		 1.20 7.70 2.22 2.12 2.13 12 19 11 13 10 11
Accrued Expenses		 0.20 2.40 1.12 0.73 2.16 8.83 57 44 47 38 38
Other Current Liabilities		 - - - - 0.00 3.48 8.35 5.36 7.09 8.96 3.38
Total Noncurrent Liabilities		 1.09 4.15 7.39 4.24 22 30 19 29 28 28 42
Long-Term Debt		 - - - - 0.00 0.00 0.18 14 15 11 11
Other Noncurrent Operating Liabilities		 0.66 4.15 7.39 4.24 22 30 18 15 13 17 31
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 16 10 4.00 13 7.09 95 138 44 39 28 19
Total Preferred & Common Equity		 16 10 4.00 13 7.09 95 138 44 39 28 19
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 16 10 4.00 13 7.09 95 138 44 39 28 19
Common Stock		 39 57 73 93 113 215 316 331 343 348 353
Retained Earnings		 -18 -47 -69 -79 -106 -120 -178 -287 -304 -320 -334

Quarterly Balance Sheets for Aytu BioPharma

This table presents Aytu BioPharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 9/30/2024 12/31/2024 3/31/2025 9/30/2025 12/31/2025 3/31/2026
Total Assets		 133 131 129 116 116 124 125 122 112
Total Current Assets		 71 71 71 61 63 73 81 76 67
Cash & Equivalents		 20 20 20 20 20 18 33 30 27
Accounts Receivable		 30 29 30 23 25 36 33 31 24
Inventories, net		 13 13 13 12 11 11 10 8.66 7.46
Prepaid Expenses		 7.04 8.11 7.25 5.73 6.17 7.46 5.15 6.64 8.66
Plant, Property, & Equipment, net		 1.72 1.13 0.97 0.69 0.52 0.55 0.50 0.48 0.41
Total Noncurrent Assets		 61 59 56 54 53 51 43 45 44
Intangible Assets		 57 56 54 51 50 49 41 44 42
Other Noncurrent Operating Assets		 3.23 3.04 1.80 3.20 2.70 2.43 1.95 1.70 1.47
Total Liabilities & Shareholders' Equity		 133 131 129 116 116 124 125 122 112
Total Liabilities		 101 98 98 86 85 89 102 108 77
Total Current Liabilities		 65 64 84 61 64 71 66 66 60
Short-Term Debt		 1.28 1.07 17 6.13 5.87 12 17 11 12
Accounts Payable		 14 10 10 14 12 12 12 14 13
Accrued Expenses		 41 43 44 34 39 42 37 40 34
Other Current Liabilities		 8.99 9.24 12 7.89 7.11 5.05 0.22 0.22 0.22
Total Noncurrent Liabilities		 35 34 14 25 21 19 36 42 17
Long-Term Debt		 15 15 0.00 10 9.98 9.54 10 10.00 9.55
Other Noncurrent Operating Liabilities		 20 19 14 14 11 9.06 25 32 7.03
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 32 33 31 30 31 35 23 14 35
Total Preferred & Common Equity		 32 33 31 30 31 35 23 14 35
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 32 33 31 30 31 35 23 14 35
Common Stock		 344 345 346 348 348 349 355 356 383
Retained Earnings		 -312 -312 -315 -318 -318 -314 -332 -342 -348

Annual Metrics And Ratios for Aytu BioPharma

This table displays calculated financial ratios and metrics derived from Aytu BioPharma's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
DEI Shares Outstanding		 173,597,365.00 44,856,459.00 13,836,607.00 35,888,069.00 16,660,395.00 120,261,423.00 25,170,596.00 38,574,875.00 3,780,179.00 5,568,158.00 6,170,246.00
DEI Adjusted Shares Outstanding		 43,399.00 11,214.00 3,459.00 8,972.00 83,302.00 601,307.00 1,258,530.00 1,928,744.00 3,780,179.00 5,568,158.00 6,170,246.00
DEI Earnings Per Adjusted Shares Outstanding		 -177.96 -2,512.94 -6,507.17 -1,135.52 -325.71 -22.65 -46.32 -56.40 -4.51 -2.85 -2.20
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 878.85% 51.45% 13.61% 100.00% 277.47% 137.52% 47.29% 11.10% -39.31% 1.84%
EBITDA Growth		 -18.96% -110.96% -190.20% 176.39% -497.20% 85.21% -570.12% -109.37% 97.26% 195.69% -275.47%
EBIT Growth		 -20.25% -184.54% -166.76% 157.80% -363.58% 74.99% -324.36% -93.16% 88.92% 60.91% -112.53%
NOPAT Growth		 3.54% -184.37% -170.90% 153.17% 28.97% -25.43% -178.60% -86.69% 84.47% 90.68% -391.95%
Net Income Growth		 0.00% -264.87% 40.25% 164.21% -332.63% 49.80% -327.93% -86.62% 84.33% 7.08% 14.40%
EPS Growth		 0.00% -3,114.50% 105.21% 123.04% 77.27% 49.80% -15.61% -86.62% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 0.00% -60.64% -59.53% -15.26% 26.46% -105.14% 8.49% -11.01% 82.21% 72.94% -39.55%
Free Cash Flow Firm Growth		 61.57% -48.23% -547.68% 119.92% 278.90% -522.66% -52.59% 92.78% 79.76% 708.64% -26.26%
Invested Capital Growth		 0.00% -88.02% 483.73% 4.09% -245.61% 869.07% 133.69% -61.64% -24.12% -32.08% -55.79%
Revenue Q/Q Growth		 0.00% 41.79% -6.10% 7.50% 1,382.57% 0.00% 15.12% 4.28% 3.15% -19.85% 0.82%
EBITDA Q/Q Growth		 -4,672.98% -167.26% 73.22% 145.12% -86,518.77% 0.00% -33.88% -0.21% 87.20% -59.19% -129.62%
EBIT Q/Q Growth		 0.00% -105.74% -83.71% 114.49% -905.50% 0.00% -28.93% 0.54% 60.60% -209.03% -225.82%
NOPAT Q/Q Growth		 0.00% -105.62% -84.20% 18.23% -265.19% 0.00% -42.08% 5.65% 50.86% -286.96% -201.37%
Net Income Q/Q Growth		 0.00% -87.39% 55.04% 125.21% -1,671.87% 0.00% -37.36% 2.60% 44.43% -15.78% -927.46%
EPS Q/Q Growth		 0.00% -3,278.91% 55.04% 89.84% -1,311.89% 0.00% -45.61% 2.60% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -37.73% -8.97% -9.13% -17.38% 14.35% 0.00% 5.42% -2.92% 76.24% -115.84% 64.96%
Free Cash Flow Firm Q/Q Growth		 24.81% 24.28% 46.32% -207.78% 290.22% -578.13% 32.84% -9.18% 91.21% -54.38% 152.77%
Invested Capital Q/Q Growth		 17.04% -90.23% -64.01% 1,764.16% -286.50% 0.00% -12.25% -19.51% -30.10% -17.18% -74.23%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 66.34% 62.65% 112.01% 131.93% 139.84% 70.03% 44.49% 54.08% 62.04% 75.26% 69.04%
EBITDA Margin		 -2,823.77% -608.57% -944.40% -561.23% -652.14% -25.55% -72.07% -102.45% -2.53% 3.98% -6.86%
Operating Margin		 -2,915.53% -847.02% -1,249.40% -1,614.72% -460.27% -76.47% -89.70% -113.69% -15.89% -2.44% -11.79%
EBIT Margin		 -2,915.53% -847.51% -1,236.19% -773.62% -726.64% -48.15% -86.03% -112.82% -11.26% -7.25% -15.13%
Profit (Net Income) Margin		 -2,950.32% -1,099.73% -1,397.34% -835.04% -741.27% -49.29% -88.81% -112.53% -15.88% -24.31% -20.43%
Tax Burden Percent		 99.69% 100.00% 200.00% 300.00% 200.00% 100.00% 100.45% 99.90% 100.00% 152.67% 98.67%
Interest Burden Percent		 101.51% 129.76% 226.07% 323.82% 204.03% 102.38% 102.78% 99.85% 141.06% 219.64% 136.88%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -64.65% -328.39% -644.28% -404.82% -222.72% -70.67% -51.33% -98.90% -31.49% -4.05% -34.18%
ROIC Less NNEP Spread (ROIC-NNEP)		 -32.28% -170.48% -470.88% -589.60% -91.31% -74.15% -3.90% 143.35% 99.49% 239.24% 76.38%
Return on Net Nonoperating Assets (RNNOA)		 22.62% 109.10% 324.68% 370.53% 103.93% 48.89% 1.21% -20.72% -9.27% -43.19% -23.92%
Return on Equity (ROE)		 -42.04% -219.29% -639.21% -121.04% -118.78% -21.78% -50.12% -119.62% -40.76% -47.24% -58.10%
Cash Return on Invested Capital (CROIC)		 -64.65% -171.17% -3,105.55% -608.88% 0.00% -143.74% -131.46% -9.80% -4.07% 34.16% 43.19%
Operating Return on Assets (OROA)		 -50.54% -102.13% -101.23% -52.35% -190.72% -14.15% -26.95% -54.08% -8.82% -3.71% -8.29%
Return on Assets (ROA)		 -51.15% -132.52% -228.85% -113.01% -194.56% -14.49% -27.83% -53.95% -12.44% -12.45% -11.20%
Return on Common Equity (ROCE)		 -42.04% -219.29% -319.61% -171.60% -175.10% -21.78% -50.12% -119.62% -40.76% -47.24% -58.10%
Return on Equity Simple (ROE_SIMPLE)		 -49.46% -279.42% -562.73% -75.89% -382.80% -14.34% -42.37% -245.51% -43.32% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -5.34 -15 -28 -14 -12 -15 -41 -77 -12 -1.11 -5.48
NOPAT Margin		 -2,040.87% -592.91% -874.58% -1,130.30% -322.19% -53.53% -62.79% -79.59% -11.12% -1.71% -8.25%
Net Nonoperating Expense Percent (NNEP)		 -32.38% -157.91% -173.41% 336.35% -131.40% 3.48% -47.43% -242.25% -130.98% -243.30% -110.56%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - - -2.60% -13.43%
Cost of Revenue to Revenue		 33.66% 37.35% 87.99% 168.07% 60.16% 29.97% 55.51% 45.92% 37.96% 24.74% 30.96%
SG&A Expenses to Revenue		 1,520.72% 332.40% 1,082.86% 1,453.44% 516.03% 71.14% 38.85% 32.24% 26.66% 30.61% 26.18%
R&D to Revenue		 1,307.71% 246.63% 83.67% 13.74% 16.09% 6.23% 8.57% 13.10% 3.81% 4.25% 2.00%
Operating Expenses to Revenue		 2,981.87% 909.67% 1,361.41% 1,164.43% 600.11% 146.50% 134.19% 167.78% 77.93% 77.70% 80.83%
Earnings before Interest and Taxes (EBIT)		 -7.63 -22 -40 -19 -53 -13 -56 -109 -12 -4.73 -10
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -7.39 -16 -30 -14 -48 -7.06 -47 -99 -2.71 2.60 -4.56
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.70 4.44 1.80 0.92 0.60 0.15 0.59 0.71
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.99 4.44 9.45 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 2.57 4.30 6.18 1.92 0.28 0.06 0.25 0.20
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.42 0.00 2.58 0.90 0.59 0.00 0.51 0.44
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.78 3.52 4.49 1.54 0.26 0.00 0.17 0.07
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.38 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 4.05 0.00 0.00 0.00 0.00 1.21 0.62
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.07 0.12 0.30 0.02 0.18 0.41 0.42 0.55 1.15
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.32 0.37 0.39 0.57
Financial Leverage		 -0.70 -0.64 -1.38 -1.34 -2.28 -0.66 -0.31 -0.14 -0.09 -0.18 -0.31
Leverage Ratio		 1.44 1.65 5.59 6.21 2.72 1.84 1.80 2.22 3.28 3.80 5.19
Compound Leverage Factor		 1.46 2.15 6.31 4.47 5.55 1.89 1.85 2.21 4.62 8.34 7.10
Debt to Total Capital		 0.00% 0.00% 6.13% 11.75% 26.40% 1.75% 15.26% 28.99% 29.36% 35.31% 53.49%
Short-Term Debt to Total Capital		 0.00% 0.00% 6.13% 7.83% 13.20% 1.75% 15.15% 6.11% 2.96% 9.92% 26.78%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.11% 22.88% 26.41% 25.39% 26.72%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 93.87% 288.25% 173.59% 98.25% 84.74% 71.01% 70.64% 64.69% 46.51%
Debt to EBITDA		 0.00 0.00 -0.02 -0.24 -0.09 -0.24 -0.52 -0.18 -6.03 5.83 -4.79
Net Debt to EBITDA		 0.00 0.00 0.04 2.88 0.43 6.61 0.53 0.01 2.44 -1.88 2.01
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.14 -5.42 4.19 -2.39
Debt to NOPAT		 0.00 0.00 -0.02 -0.10 -0.16 -0.11 -0.60 -0.24 -1.37 -13.58 -3.98
Net Debt to NOPAT		 0.00 0.00 0.04 1.43 1.73 3.15 0.61 0.02 0.55 4.38 1.67
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.19 -1.23 -9.77 -1.99
Altman Z-Score		 0.00 0.00 0.00 -11.43 -5.58 0.92 -0.82 -4.70 -2.57 -3.27 -3.26
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.44 1.00 1.68 5.58 5.75 2.62 0.96 0.93 1.03 0.99 1.26
Quick Ratio		 5.08 0.92 0.74 6.71 2.38 1.87 0.71 0.64 0.75 0.70 0.98
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -5.34 -7.92 -34 -21 16 -69 -106 -7.62 -1.54 9.39 6.92
Operating Cash Flow to CapEx		 0.00% -824.29% -1,605.10% -6,715.86% -4,941.12% 0.00% -1,109.10% 0.00% 0.00% -421.88% 0.00%
Free Cash Flow to Firm to Interest Expense		 -46.46 -1.44 -26.79 -83.03 30.56 -218.88 -67.27 0.00 -0.31 1.66 1.87
Operating Cash Flow to Interest Expense		 -57.69 -1.94 -5.46 -63.81 -51.66 -89.79 -16.55 0.00 -1.03 -0.25 -0.52
Operating Cash Flow Less CapEx to Interest Expense		 -57.69 -2.18 -11.59 -65.71 -53.75 -89.79 -18.04 0.00 -1.03 -0.30 -0.40
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.02 0.12 0.33 0.61 0.53 0.29 0.31 0.48 0.78 0.51 0.55
Accounts Receivable Turnover		 0.00 16.04 18.66 19.84 12.62 7.49 3.88 3.88 4.24 2.48 2.43
Inventory Turnover		 0.00 3.39 3.09 4.64 3.17 1.45 2.77 3.27 3.57 1.34 1.74
Fixed Asset Turnover		 6.02 19.63 14.67 16.91 69.32 0.00 0.00 0.00 44.38 51.98 108.38
Accounts Payable Turnover		 0.07 0.22 0.57 2.83 2.07 1.20 2.36 2.94 3.33 1.36 1.97
Days Sales Outstanding (DSO)		 0.00 22.75 78.23 110.38 115.66 48.70 94.01 94.18 86.07 146.89 150.33
Days Inventory Outstanding (DIO)		 0.00 107.57 473.05 707.87 460.64 252.10 131.94 111.79 102.26 273.10 209.35
Days Payable Outstanding (DPO)		 4,983.40 1,696.65 1,277.65 1,158.81 718.56 303.55 154.76 124.34 109.52 269.21 185.73
Cash Conversion Cycle (CCC)		 -4,983.40 -1,566.32 -2,004.03 -285.37 -128.69 -2.75 71.18 81.63 78.81 150.78 173.95
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 8.26 0.99 6.77 14 -6.26 48 112 43 33 22 9.83
Invested Capital Turnover		 0.03 0.55 2.95 1.07 1.38 1.32 0.82 1.24 2.83 2.37 4.14
Increase / (Decrease) in Invested Capital		 0.00 -7.27 12 14 -40 54 64 -69 -10 -11 -12
Enterprise Value (EV)		 0.00 0.00 0.00 2.85 21 124 101 25 -0.58 11 4.31
Market Capitalization		 0.00 0.00 0.00 9.42 31 171 126 27 6.05 16 13
Book Value per Share		 $0.09 $0.22 $0.58 $20.54 $1.33 $0.79 $5.47 $1.15 $10.41 $4.98 $3.07
Tangible Book Value per Share		 $0.09 $0.21 $0.48 $20.17 $0.85 $0.15 ($0.54) ($0.68) ($5.19) ($4.44) ($3.77)
Total Capital		 16 10 4.26 14 16 97 162 62 56 43 41
Total Debt		 0.00 0.00 0.52 1.09 2.16 1.70 25 18 16 15 22
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.18 14 15 11 11
Net Debt		 -7.35 -9.10 -1.23 -13 -20 -47 -25 -1.27 -6.62 -4.88 -9.14
Capital Expenditures (CapEx)		 0.00 1.29 1.72 0.95 1.12 0.00 2.34 0.00 0.00 0.33 -0.44
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.79 -9.08 -2.40 -0.98 -0.31 0.02 -30 -20 -19 -16 -3.92
Debt-free Net Working Capital (DFNWC)		 6.56 0.02 -0.32 13 22 48 20 -0.70 3.71 3.92 27
Net Working Capital (NWC)		 6.56 0.02 -1.16 12 20 47 -4.20 -4.51 2.06 -0.34 16
Net Nonoperating Expense (NNE)		 2.38 13 17 -3.60 31 -1.17 17 32 5.11 15 8.08
Net Nonoperating Obligations (NNO)		 -7.35 -9.10 -1.23 -13 -20 -47 -25 -1.17 -6.62 -5.49 -9.14
Total Depreciation and Amortization (D&A)		 0.24 6.12 9.40 2.59 5.45 6.25 9.16 10 9.37 7.32 5.49
Debt-free, Cash-free Net Working Capital to Revenue		 -301.10% -354.34% -74.39% -40.16% -4.26% 0.08% -44.95% -20.75% -17.95% -24.69% -5.90%
Debt-free Net Working Capital to Revenue		 2,507.75% 0.62% -19.91% 542.82% 304.31% 174.99% 31.08% -0.72% 3.46% 6.01% 40.73%
Net Working Capital to Revenue		 2,507.75% 0.62% -36.13% 497.98% 274.86% 168.86% -6.41% -4.67% 1.92% -0.52% 24.28%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($3,360.00) ($64,720.00) ($193,248.30) ($3,077.31) ($699.48) ($60.00) ($69.60) ($67.80) ($5.11) ($2.86) ($2.16)
Adjusted Weighted Average Basic Shares Outstanding		 3.57K 1.27K 1.01K 9.01K 88.44K 629.19K 1.38M 1.47M 3.34M 5.54M 6.28M
Adjusted Diluted Earnings per Share		 ($3,360.00) ($64,720.00) ($193,248.30) ($3,077.31) ($699.48) ($60.00) ($69.60) ($75.00) ($5.11) $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 3.57K 1.27K 4.02M 9.01K 88.44K 629.19K 1.38M 1.47M 3.34M 6.15M 9.91M
Adjusted Basic & Diluted Earnings per Share		 ($3,360.00) ($64,720.00) ($193,248.30) ($3,077.31) ($699.48) ($60.00) ($69.60) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 2.30K 435.00 466.14K 668.93K 38.97K 225.96K 837.33K 3.12M 5.53M 6.15M 9.91M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.34 -9.94 -26 -25 -24 -13 -27 -24 -8.63 0.40 1.78
Normalized NOPAT Margin		 -2,040.87% -388.03% -819.60% -1,023.81% -322.19% -45.40% -40.79% -24.94% -8.04% 0.61% 2.68%
Pre Tax Income Margin		 -2,959.45% -1,099.73% -1,397.34% -556.70% -741.27% -49.29% -88.42% -112.64% -15.88% -15.92% -20.71%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -66.37 -3.95 -7.86 -37.78 -49.67 -42.10 -35.99 0.00 -2.44 -0.84 -2.71
NOPAT to Interest Expense		 -46.46 -2.77 -5.56 -36.80 -44.04 -46.81 -26.26 0.00 -2.41 -0.20 -1.48
EBIT Less CapEx to Interest Expense		 -66.37 -4.19 -8.20 -39.68 -101.42 -42.10 -37.48 0.00 -2.44 -0.89 -2.59
NOPAT Less CapEx to Interest Expense		 -46.46 -3.00 -5.90 -57.10 -23.07 -46.81 -27.76 0.00 -2.41 -0.26 -1.36
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 -0.61% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.61% 0.00% -0.40% 0.00% -5.45% -39.67% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Aytu BioPharma

This table displays calculated financial ratios and metrics derived from Aytu BioPharma's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 5,530,027.00 5,567,490.00 5,567,597.00 5,568,158.00 6,148,993.00 6,149,369.00 6,169,848.00 6,170,246.00 9,911,913.00 - 10,733,208.00
DEI Adjusted Shares Outstanding		 5,530,027.00 5,567,490.00 5,567,597.00 5,568,158.00 6,148,993.00 6,149,369.00 6,169,848.00 6,170,246.00 9,911,913.00 - 10,733,208.00
DEI Earnings Per Adjusted Shares Outstanding		 -1.47 -0.04 -0.52 -0.83 0.24 0.13 0.65 -3.21 0.20 - -0.52
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -35.57% -28.66% -38.31% -52.52% -6.98% -13.48% 31.57% 3.71% -16.21% -6.51% -32.74%
EBITDA Growth		 -318.45% 197.82% 124.11% -78.98% 201.08% -34.15% 409.46% -1,835.83% -14.02% -427.58% -166.71%
EBIT Growth		 -783.02% 139.82% 92.92% -127.53% 140.26% -45.18% 1,025.10% -2,612.03% -0.44% -786.11% -209.62%
NOPAT Growth		 52.05% 128.95% 81.34% -1,444.97% -11.81% -311.98% 323.49% -235.37% -121.64% 53.27% -213.87%
Net Income Growth		 -1,058.35% 96.71% 59.90% -87.91% 118.15% 458.18% 238.34% -329.24% 33.31% -1,443.15% -240.66%
EPS Growth		 -428.57% 0.00% 0.00% -12.16% 89.86% -550.00% 140.38% 0.00% 46.67% -303.85% -352.38%
Operating Cash Flow Growth		 97.69% 94.47% 91.26% -108.41% -463.98% 2,251.85% -2,441.34% 455.71% 48.07% 26.51% 35.21%
Free Cash Flow Firm Growth		 -62.03% -54.36% 2,345.57% -15.31% -92.47% -99.03% -146.66% -20.71% 415.41% 9,903.04% 157.43%
Invested Capital Growth		 -39.88% -39.28% -42.67% -32.08% -7.23% -10.72% 42.10% -55.79% -32.57% -80.53% -20.71%
Revenue Q/Q Growth		 -42.02% 5.23% -25.19% 4.05% 13.58% -2.13% 13.75% -17.98% -8.24% 9.20% -18.16%
EBITDA Q/Q Growth		 -179.95% 210.78% -71.96% -15.37% 284.53% -27.82% 116.90% -386.92% 119.05% -374.98% 55.83%
EBIT Q/Q Growth		 -347.01% 143.05% -119.14% -35.29% 461.16% -41.37% 222.93% -496.63% 113.26% -504.03% 48.40%
NOPAT Q/Q Growth		 -613.02% 329.36% -180.31% -42.33% 57.35% -334.85% 184.67% -313.58% 71.81% 8.31% -106.29%
Net Income Q/Q Growth		 -230.48% 97.29% -1,212.27% -59.92% 131.93% -46.54% 406.85% -596.19% 109.92% -638.63% 46.92%
EPS Q/Q Growth		 -100.00% 97.30% -1,200.00% -59.62% 81.93% -73.33% 180.77% 0.00% 0.00% -1,212.50% 49.52%
Operating Cash Flow Q/Q Growth		 -102.25% 36.02% -88.15% -210.24% -51.02% 344.12% -322.20% 143.42% -122.05% 694.66% -213.80%
Free Cash Flow Firm Q/Q Growth		 72.79% 12.17% -7.49% -52.77% -84.64% -85.58% -4,562.00% 180.27% -0.18% 179.80% -74.38%
Invested Capital Q/Q Growth		 -13.48% 3.69% -8.59% -17.18% 18.19% -0.21% 45.49% -74.23% 80.26% -71.18% 492.34%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 73.18% 77.89% 73.88% 75.73% 72.31% 66.49% 69.40% 67.75% 66.14% 63.46% 61.23%
EBITDA Margin		 -21.40% 22.53% 8.44% 6.87% 23.25% 17.14% 32.69% -114.92% 23.86% -60.07% -32.42%
Operating Margin		 -4.87% 16.78% -11.39% -15.58% -5.61% -10.45% 13.12% -50.37% -10.83% -12.99% -32.75%
EBIT Margin		 -34.74% 14.21% -3.64% -4.73% 15.04% 9.01% 25.57% -123.64% 17.86% -66.10% -41.67%
Profit (Net Income) Margin		 -45.57% -1.17% -20.58% -31.64% 8.89% 4.86% 21.65% -130.94% 14.15% -69.79% -45.27%
Tax Burden Percent		 108.66% -15.73% 163.38% 181.99% 98.40% 206.28% 104.61% 101.93% 100.00% 100.00% 100.18%
Interest Burden Percent		 120.73% 52.50% 346.47% 367.68% 60.11% 26.15% 80.92% 103.90% 79.20% 105.59% 108.43%
Effective Tax Rate		 0.00% 55.75% 0.00% 0.00% 27.04% -74.08% -3.20% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -8.81% 17.20% -17.60% -25.86% -9.59% -40.20% 27.43% -146.00% -31.36% -36.37% -37.94%
ROIC Less NNEP Spread (ROIC-NNEP)		 286.75% 362.01% -196.11% 24.12% -67.80% -133.29% -408.61% 52.08% -108.41% 98.59% 298.00%
Return on Net Nonoperating Assets (RNNOA)		 -18.11% -4.30% -5.42% -4.35% 8.09% 16.83% 4.27% -16.31% 18.42% -29.91% -7.02%
Return on Equity (ROE)		 -26.92% 12.90% -23.02% -30.21% -1.50% -23.37% 31.70% -162.32% -12.94% -66.28% -44.96%
Cash Return on Invested Capital (CROIC)		 19.89% 37.88% 55.87% 34.16% 3.26% -5.03% -40.37% 43.19% 12.17% 96.02% -7.93%
Operating Return on Assets (OROA)		 -23.96% 9.39% -2.14% -2.42% 7.73% 4.47% 13.30% -67.75% 9.45% -34.76% -20.00%
Return on Assets (ROA)		 -31.44% -0.77% -12.13% -16.20% 4.57% 2.41% 11.26% -71.76% 7.48% -36.70% -21.72%
Return on Common Equity (ROCE)		 -26.92% 12.90% -23.02% -30.21% -1.50% -23.37% 31.70% -162.32% -12.94% -66.28% -44.96%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.61 1.39 -1.12 -1.59 -0.68 -2.95 2.50 -5.34 -1.50 -1.38 -2.84
NOPAT Margin		 -3.41% 7.42% -7.97% -10.90% -4.09% -18.19% 13.54% -35.26% -10.83% -9.09% -22.92%
Net Nonoperating Expense Percent (NNEP)		 -295.56% -344.81% 178.52% -49.98% 58.21% 93.10% 436.05% -198.08% 77.05% -134.96% -335.94%
Return On Investment Capital (ROIC_SIMPLE)		 -1.26% 2.85% -2.35% -3.71% -1.46% -6.33% 4.44% -13.08% -2.99% -3.93% -4.99%
Cost of Revenue to Revenue		 26.82% 22.11% 26.12% 24.27% 27.69% 33.51% 30.60% 32.25% 33.86% 36.54% 38.77%
SG&A Expenses to Revenue		 35.33% 25.60% 34.45% 27.60% 30.92% 27.43% 22.27% 24.42% 35.46% 33.43% 40.07%
R&D to Revenue		 3.34% 2.78% 4.36% 7.14% 2.57% 3.22% 0.88% 1.43% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 78.04% 61.11% 85.26% 91.31% 77.92% 76.94% 56.28% 118.12% 76.97% 76.45% 93.97%
Earnings before Interest and Taxes (EBIT)		 -6.19 2.67 -0.51 -0.69 2.49 1.46 4.72 -19 2.48 -10 -5.17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -3.81 4.22 1.18 1.00 3.85 2.78 6.03 -17 3.31 -9.11 -4.02
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.32 0.48 0.55 0.59 0.48 0.34 0.21 0.71 0.80 1.87 0.83
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.10 0.18 0.21 0.25 0.23 0.17 0.11 0.20 0.29 0.42 0.52
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 4.52 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 22.14% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.22 0.42 0.52 0.51 0.41 0.23 0.28 0.44 0.74 3.41 0.81
Enterprise Value to Revenue (EV/Rev)		 0.07 0.14 0.17 0.17 0.17 0.10 0.16 0.07 0.21 0.28 0.43
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 45.82 2.18 4.38 1.06 0.67 0.78 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 2.75 2.15 1.33 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 23.30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 1.67 2.02 1.58 0.00 0.00 8.78 0.00 0.00 0.00 0.00 14.54
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.85 0.84 0.67 1.21 12.26 0.00 0.00 0.62 4.93 1.16 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.50 0.49 0.54 0.55 0.56 0.52 0.61 1.15 1.17 1.47 0.62
Long-Term Debt to Equity		 0.46 0.46 0.00 0.39 0.35 0.32 0.27 0.57 0.45 0.70 0.27
Financial Leverage		 -0.06 -0.01 0.03 -0.18 -0.12 -0.13 -0.01 -0.31 -0.17 -0.30 -0.02
Leverage Ratio		 3.51 3.47 3.85 3.80 4.01 3.89 3.85 5.19 4.54 5.30 3.37
Compound Leverage Factor		 4.24 1.82 13.34 13.95 2.41 1.02 3.12 5.39 3.60 5.59 3.65
Debt to Total Capital		 33.38% 32.81% 35.20% 35.31% 35.70% 34.00% 38.03% 53.49% 53.98% 59.58% 38.30%
Short-Term Debt to Total Capital		 2.64% 2.18% 35.20% 9.92% 13.21% 12.59% 21.10% 26.78% 33.23% 31.12% 21.54%
Long-Term Debt to Total Capital		 30.74% 30.63% 0.00% 25.39% 22.49% 21.41% 16.93% 26.72% 20.75% 28.46% 16.76%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 66.62% 67.19% 64.80% 64.69% 64.30% 66.00% 61.97% 46.51% 46.02% 40.42% 61.70%
Debt to EBITDA		 -1.95 59.64 2.63 5.83 1.61 1.80 1.57 -4.79 -5.33 -1.23 -0.81
Net Debt to EBITDA		 0.46 -12.96 -0.48 -1.88 -0.35 -0.52 0.24 2.01 1.07 0.54 0.18
Long-Term Debt to EBITDA		 -1.79 55.68 0.00 4.19 1.02 1.13 0.70 -2.39 -2.05 -0.59 -0.35
Debt to NOPAT		 -1.43 -3.75 28.06 -13.58 -14.30 -3.49 -11.78 -3.98 -4.62 -3.45 -2.06
Net Debt to NOPAT		 0.34 0.82 -5.11 4.38 3.07 1.00 -1.79 1.67 0.93 1.50 0.46
Long-Term Debt to NOPAT		 -1.32 -3.50 0.00 -9.77 -9.01 -2.20 -5.24 -1.99 -1.78 -1.65 -0.90
Altman Z-Score		 -2.60 -2.42 -2.82 -3.16 -3.13 -3.19 -2.81 -3.49 -2.88 -3.43 -3.70
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.08 1.11 0.85 0.99 0.99 0.98 1.03 1.26 1.23 1.16 1.12
Quick Ratio		 0.76 0.76 0.59 0.70 0.71 0.72 0.76 0.98 1.00 0.93 0.85
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 18 20 19 8.91 1.37 0.20 -8.80 7.07 7.05 20 5.06
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% -239.51% 0.00% 0.00% -9,355.07% 16,488.24% 0.00% 21,617.65% 0.00%
Free Cash Flow to Firm to Interest Expense		 14.17 16.11 15.01 4.82 1.38 0.18 -9.78 9.68 13.67 35.24 11.59
Operating Cash Flow to Interest Expense		 -0.16 -0.11 -0.20 -0.43 -1.20 2.69 -7.17 3.84 -1.20 6.56 -9.59
Operating Cash Flow Less CapEx to Interest Expense		 -0.16 -0.11 -0.20 -0.60 -0.81 2.83 -7.25 3.82 -1.20 6.53 -9.59
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.69 0.66 0.59 0.51 0.51 0.50 0.52 0.55 0.53 0.53 0.48
Accounts Receivable Turnover		 3.38 3.28 2.54 2.48 2.41 2.24 2.00 2.43 2.26 2.22 1.88
Inventory Turnover		 2.78 2.40 1.85 1.34 1.29 1.43 1.58 1.74 1.89 2.10 2.15
Fixed Asset Turnover		 0.00 0.00 0.00 51.98 52.97 74.76 87.03 108.38 106.87 125.28 118.78
Accounts Payable Turnover		 2.47 2.95 1.97 1.36 1.14 1.55 1.71 1.97 1.60 1.60 1.58
Days Sales Outstanding (DSO)		 108.13 111.39 143.55 146.89 151.39 162.87 182.25 150.33 161.55 164.10 194.48
Days Inventory Outstanding (DIO)		 131.26 152.37 197.79 273.10 282.87 255.13 230.38 209.35 192.88 173.46 169.52
Days Payable Outstanding (DPO)		 148.00 123.61 185.39 269.21 320.36 234.86 213.90 185.73 228.35 228.09 231.19
Cash Conversion Cycle (CCC)		 91.39 140.15 155.95 150.78 113.90 183.14 198.73 173.95 126.08 109.48 132.81
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 28 29 27 22 26 26 38 9.83 18 5.11 30
Invested Capital Turnover		 2.59 2.32 2.21 2.37 2.34 2.21 2.03 4.14 2.90 4.00 1.66
Increase / (Decrease) in Invested Capital		 -19 -19 -20 -11 -2.05 -3.15 11 -12 -8.56 -21 -7.90
Enterprise Value (EV)		 6.36 12 14 11 11 5.91 11 4.31 13 17 24
Market Capitalization		 10 16 17 16 14 10 7.40 13 19 26 29
Book Value per Share		 $8.51 $5.90 $5.53 $4.98 $4.85 $5.00 $5.66 $3.07 $2.34 $1.39 $3.27
Tangible Book Value per Share		 ($6.66) ($4.11) ($4.19) ($4.44) ($3.48) ($3.12) ($2.24) ($3.77) ($1.84) ($2.88) ($0.68)
Total Capital		 48 49 47 43 46 47 56 41 50 35 57
Total Debt		 16 16 17 15 17 16 21 22 27 21 22
Total Long-Term Debt		 15 15 0.00 11 10 9.98 9.54 11 10 10.00 9.55
Net Debt		 -3.85 -3.49 -3.04 -4.88 -3.55 -4.55 3.25 -9.14 -5.45 -9.10 -4.90
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.33 -0.38 -0.15 0.07 0.02 0.00 0.02 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -14 -11 -16 -16 -14 -16 -4.48 -3.92 -0.78 -8.42 -7.09
Debt-free Net Working Capital (DFNWC)		 6.41 8.25 4.16 3.92 5.61 4.87 14 27 32 22 20
Net Working Capital (NWC)		 5.14 7.18 -13 -0.34 -0.51 -1.00 1.81 16 15 11 7.35
Net Nonoperating Expense (NNE)		 7.51 1.61 1.77 3.03 -2.15 -3.74 -1.50 14 -3.47 9.21 2.77
Net Nonoperating Obligations (NNO)		 -3.85 -3.49 -3.93 -5.49 -3.55 -4.55 3.25 -9.14 -5.45 -9.10 -4.90
Total Depreciation and Amortization (D&A)		 2.38 1.56 1.69 1.69 1.36 1.32 1.31 1.32 0.83 0.91 1.15
Debt-free, Cash-free Net Working Capital to Revenue		 -13.89% -12.53% -19.19% -24.69% -22.67% -25.28% -6.81% -5.90% -1.23% -13.43% -12.53%
Debt-free Net Working Capital to Revenue		 6.57% 9.16% 5.11% 6.01% 8.78% 7.94% 20.79% 40.73% 50.00% 34.50% 34.67%
Net Working Capital to Revenue		 5.26% 7.98% -15.44% -0.52% -0.80% -1.62% 2.74% 24.28% 23.73% 17.05% 12.99%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.48) ($0.04) ($0.52) ($0.83) $0.24 $0.13 $0.65 ($3.18) $0.21 ($1.05) ($0.53)
Adjusted Weighted Average Basic Shares Outstanding		 5.48M 5.52M 5.53M 5.54M 6.07M 6.13M 6.13M 6.28M 9.44M 10.04M 10.51M
Adjusted Diluted Earnings per Share		 ($1.48) $0.00 $0.00 ($0.83) ($0.15) ($0.26) $0.21 $0.00 ($0.08) ($1.05) ($0.53)
Adjusted Weighted Average Diluted Shares Outstanding		 5.48M 5.57M 5.57M 6.15M 9.10M 8.49M 8.20M 9.91M 19.48M 10.04M 10.51M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($0.83) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 5.57M 5.57M 5.57M 6.15M 6.15M 6.17M 6.17M 9.91M 10.19M 10.73M 10.73M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.61 2.20 -0.95 -0.25 -0.11 -0.26 1.69 -5.34 -1.05 -1.38 -2.84
Normalized NOPAT Margin		 -3.41% 11.75% -6.75% -1.73% -0.64% -1.63% 9.18% -35.26% -7.58% -9.09% -22.92%
Pre Tax Income Margin		 -41.94% 7.46% -12.60% -17.39% 9.04% 2.36% 20.69% -128.46% 14.15% -69.79% -45.19%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -4.82 2.11 -0.41 -0.37 2.51 1.35 5.24 -25.63 4.81 -17.90 -11.86
NOPAT to Interest Expense		 -0.47 1.10 -0.89 -0.86 -0.68 -2.73 2.78 -7.31 -2.91 -2.46 -6.52
EBIT Less CapEx to Interest Expense		 -4.82 2.11 -0.41 -0.55 2.89 1.49 5.17 -25.66 4.81 -17.93 -11.86
NOPAT Less CapEx to Interest Expense		 -0.47 1.10 -0.89 -1.04 -0.30 -2.60 2.70 -7.33 -2.91 -2.49 -6.52
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Aytu BioPharma’s latest quarter shows a mixed picture: revenue held up fairly well, but the company swung back to a sizeable loss and negative operating cash flow. The balance sheet still shows a meaningful cash position, but leverage and short-term liabilities remain elevated.

  • Q3 2026 revenue was $12.4 million, down only modestly from $15.2 million in Q2 2026 and $15.1 million in Q4 2025, showing the business is still generating meaningful sales.
  • Gross profit in Q3 2026 was $7.6 million, which implies a gross margin of about 61%, a solid level for a small biotech/pharma company.
  • Cash and equivalents were $26.7 million at the end of Q3 2026, giving the company some near-term liquidity.
  • Total assets of $111.7 million versus total liabilities of $76.5 million left AYTU with positive book equity of $35.1 million in Q3 2026.
  • Operating expenses in Q3 2026 were lower than in prior quarters, with SG&A and marketing both below Q2 2026 levels.
  • Earlier periods showed the company can generate profitability: Q1 2026 posted net income of $2.0 million and Q3 2025 posted net income of $4.0 million.
  • The company’s cost of revenue has stayed fairly consistent as a percentage of sales, suggesting some stability in the core business model.
  • Share count has varied significantly across periods, which can affect EPS comparisons and may reflect financing activity or dilution-related items.
  • Management appears to be actively managing the capital structure, with recurring debt issuances and repayments across the last several quarters.
  • Q3 2026 net loss widened to $5.6 million after a profitable Q1 2026, showing earnings remain volatile.
  • Operating cash flow turned negative in Q3 2026 at negative $4.2 million, compared with positive operating cash flow in Q2 2026.
  • Accrued expenses were very large at $34.3 million in Q3 2026, a sign of substantial short-term obligations.
  • Total current liabilities were $60.0 million versus current assets of $67.3 million, leaving only a modest current cushion.
  • Debt remains significant, including $12.3 million of short-term debt and $9.5 million of long-term debt in Q3 2026.
  • Retained earnings remain deeply negative at $347.8 million in Q3 2026, reflecting a long history of cumulative losses.
  • Compared with Q3 2025, revenue fell from $18.5 million to $12.4 million, indicating weaker top-line momentum over the past year.

Bottom line: AYTU is still operating with a workable cash balance, but the latest quarter shows pressure on both profitability and cash generation. Investors should watch whether revenue stabilizes and whether the company can reduce losses without relying too heavily on financing activity.

07/30/26 03:54 AM ETAI Generated. May Contain Errors.

Aytu BioPharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Aytu BioPharma's financial year ends in June. Their financial year 2025 ended on June 30, 2025.

Aytu BioPharma's net income appears to be on an upward trend, with a most recent value of -$13.56 million in 2025, rising from -$7.72 million in 2015. The previous period was -$15.84 million in 2024. Find out what analysts predict for Aytu BioPharma in the coming months.

Aytu BioPharma's total operating income in 2025 was -$7.83 million, based on the following breakdown:
  • Total Gross Profit: $45.83 million
  • Total Operating Expenses: $53.66 million

Over the last 10 years, Aytu BioPharma's total revenue changed from $261.78 thousand in 2015 to $66.38 million in 2025, a change of 25,257.7%.

Aytu BioPharma's total liabilities were at $105.21 million at the end of 2025, a 16.4% increase from 2024, and a 3,995.5% increase since 2015.

In the past 10 years, Aytu BioPharma's cash and equivalents has ranged from $802.33 thousand in 2017 to $49.65 million in 2021, and is currently $30.95 million as of their latest financial filing in 2025.

Over the last 10 years, Aytu BioPharma's book value per share changed from 0.09 in 2015 to 3.07 in 2025, a change of 3,315.3%.


Related Companies

Financial statements for NASDAQ:AYTU last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Pass by August 7… or wait until 2027?
Right now, your phone is recording exactly where you are. It does this roughly every two minutes. Precise coor...
Crypto 101 Media | Sponsoredtc pixel
The invention Elon called the greatest in history
Jeff Brown and Marc Chaikin - two investors who called Nvidia a decade ago - say Elon Musk's newly filed AI pa...
Brownstone Research | Sponsoredtc pixel
This Quiet Metals Story Is Starting To Stack Up
A small North American mining company just hit 57-for-57 on exploration drilling—and that's only part of the s...
i2i Marketing Group, LLC | Sponsoredtc pixel
SpaceX just minted 4,400 millionaires
SpaceX's $1.75 trillion IPO turned more than 4400 employees into millionaires, according to The New York Times...
The Oxford Club | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel